| Name | Title | Contact Details |
|---|
At Elite Body Sculpture our biggest focus is making sure that every client that walks out the door is not just satisfied, but elated with their new, trimmer, sexier body. How do we do that? Mainly, we focus on liposuction and ONLY liposuction. At ...
Creating precisely tuned medicines so patients can breathe freely, we are pioneering a new therapeutic approach to treat debilitating ear, nose and throat diseases that impact the lives of millions of people. Lyra Therapeutics is a clinical-stage company pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people. Our goal is to transform the ENT treatment paradigm by providing effective front-line solutions for physicians and new treatment options for their patients. Lyra`s transmucosal therapeutic system, now being evaluated in a clinical study, directly targets tissues that are difficult or impossible to access with existing therapies. Building on expertise in materials science, drug development and formulation, the Lyra team has developed a proprietary platform that enables sustained, local delivery of medications over an extended period of time. Based on clinical results, this new therapeutic approach has the potential to provide significantly improved patient outcomes beyond the limited treatment and surgical options currently available for ENT diseases. Headquartered in the Boston area, Lyra Therapeutics was founded by George Whitesides and Robert Langer, academic luminaries in the fields of chemistry, materials science and biotechnology, and is backed by leading life science investors.
Flexicon America is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dauntless Pharmaceuticals, Inc is a San Diego, CA-based biopharmaceutical company. The traditional biotech company holds numerous assets at various stages of development, and its investors, management, labs, and staff collectively share interest in all company assets. In contrast, Dauntless uses a one-asset, one-company model.
Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.